Ushering in a new generation of vaccines - simpler, safer and more effective.
Headlines
October 2014: PDS CEO to present at the World Vaccine Congress, Belgium on October 13, 2014. Dr. Bedu-Addo will review the development of PDS’s clinical-stage HPV-cancer immunotherapy.
October 2014: PDS Scientist to present at AAPS, National Meeting, San Diego. Dr. M. Keough will be giving a talk on the Characterization of Immune Modulating Nanoparticles on November 6, 2014.
February 11, 2014: PDS Biotechnology Announces Treatment of First Patient with PDS0101. The first patient has been successfully vaccinated with the PDS0101 cancer immunotherapy in a Phase 1 clinical trial in patients with cervical intraepithelial neoplasia.
November 1, 2013: PDS Biotechnology Initiates Phase 1 Human Clinical Trials for PDS0101. PDS has initiated patient recruitment for its HPV cancer immunotherapy. The trial is being performed at multiple sites in the US. The product is based on the company’s novel Versamune® vector which was shown in preclinical studies to be very safe and effective in treating cancer.
June 2012: PDS grants Merck KGaA license to utilize Versamune™ in cancer vaccines. PDS granted Merck KGaA, Darmstadt, Germany, an exclusive worldwide license to utilize PDS’s novel Versamune™ nanotechnology platform in two of Merck’s investigational antigen-specific cancer immunotherapies.

Welcome to PDS Biotechnology Corporation

PDS Biotechnology is a clinical stage Biopharmaceutical Company developing the next-generation of simpler, safer and more effective treatments and preventions for cancer and chronic infectious diseases.

To see how Versamune™ works, please click here.

Stimulating the immune system has been demonstrated to be one of the most promising approaches to treating cancer and several debilitating and chronic infectious diseases such as hepatitis and HIV.

PDS Biotechnology has developed a simple and synthetic nanoparticle platform vector known as Versamune®. This novel and superior cancer and vaccine nanotechnology platform is very effective in training the immune system to recognize and fight the particular disease (see video on how Versamune® works). To do so, a unique protein from the particular cancer type or virus is formulated and injected with Versamune®. In pre-clinical studies very effective and superior treatment of advanced aggressive cancers with low doses of the Versamune®-based products has been demonstrated. The preclinical studies also demonstrated that the Versamune®-based products are exceptionally safe and well tolerated. Versamune® is the first synthetic immunotherapy and vaccine vector to demonstrate potent disease killing T-cell responses without the need for the addition of immune activators known as adjuvants.

PDS Biotechnology is initially applying the Versamune® vector to the treatment of HPV related cancers such as cervical cancer, oral cancer and cervical intraepithelial neoplasia (pre-cervical cancer). PDS’s lead HPV cancer immunotherapy product, PDS0101 is currently in phase 1 human clinical trials at multiple clinics within the US.

PDS Biotechnology has also demonstrated superior efficacy with a novel and rapid acting Versamune®-based preventive pandemic influenza vaccine.

In 2012, PDS signed a licensing agreement with a global pharmaceutical company, Merck KGaA, granting it a license to utilize PDS Biotechnology’s Versamune® vector in the development of two new cancer immunotherapies.